ID   FANCL_HUMAN             Reviewed;         375 AA.
AC   Q9NW38; Q6GU60;
DT   10-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   15-MAR-2017, entry version 150.
DE   RecName: Full=E3 ubiquitin-protein ligase FANCL;
DE            EC=2.3.2.27 {ECO:0000269|PubMed:12973351, ECO:0000269|PubMed:16916645, ECO:0000269|PubMed:19111657, ECO:0000269|PubMed:19589784};
DE   AltName: Full=Fanconi anemia group L protein;
DE   AltName: Full=Fanconi anemia-associated polypeptide of 43 kDa;
DE            Short=FAAP43;
DE   AltName: Full=RING-type E3 ubiquitin transferase FANCL {ECO:0000305};
GN   Name=FANCL; Synonyms=PHF9;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain, and Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   IDENTIFICATION BY MASS SPECTROMETRY IN A BRAFT COMPLEX WITH FANCA;
RP   FANCC; FANCE; FANCF AND FANCG.
RX   PubMed=12724401; DOI=10.1128/MCB.23.10.3417-3426.2003;
RA   Meetei A.R., Sechi S., Wallisch M., Yang D., Young M.K., Joenje H.,
RA   Hoatlin M.E., Wang W.;
RT   "A multiprotein nuclear complex connects Fanconi anemia and Bloom
RT   syndrome.";
RL   Mol. Cell. Biol. 23:3417-3426(2003).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, INVOLVEMENT IN
RP   FANCL, INTERACTION WITH FANCA; FANCC; FANCF AND FANCG, AND MUTAGENESIS
RP   OF CYS-307 AND CYS-310.
RX   PubMed=12973351; DOI=10.1038/ng1241;
RA   Meetei A.R., de Winter J.P., Medhurst A.L., Wallisch M., Waisfisz Q.,
RA   van de Vrugt H.J., Oostra A.B., Yan Z., Ling C., Bishop C.E.,
RA   Hoatlin M.E., Joenje H., Wang W.;
RT   "A novel ubiquitin ligase is deficient in Fanconi anemia.";
RL   Nat. Genet. 35:165-170(2003).
RN   [6]
RP   IDENTIFICATION IN A COMPLEX WITH FANCA; FANCB; FANCC; FANCE; FANCF AND
RP   FANCLG.
RX   PubMed=15502827; DOI=10.1038/ng1458;
RA   Meetei A.R., Levitus M., Xue Y., Medhurst A.L., Zwaan M., Ling C.,
RA   Rooimans M.A., Bier P., Hoatlin M., Pals G., de Winter J.P., Wang W.,
RA   Joenje H.;
RT   "X-linked inheritance of Fanconi anemia complementation group B.";
RL   Nat. Genet. 36:1219-1224(2004).
RN   [7]
RP   IDENTIFICATION IN A COMPLEX WITH FANCA; FANCB; FANCC; FANCE; FANCF;
RP   FANCG AND FANCM.
RX   PubMed=16116422; DOI=10.1038/ng1626;
RA   Meetei A.R., Medhurst A.L., Ling C., Xue Y., Singh T.R., Bier P.,
RA   Steltenpool J., Stone S., Dokal I., Mathew C.G., Hoatlin M.,
RA   Joenje H., de Winter J.P., Wang W.;
RT   "A human ortholog of archaeal DNA repair protein Hef is defective in
RT   Fanconi anemia complementation group M.";
RL   Nat. Genet. 37:958-963(2005).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH UBE2T, UBIQUITINATION,
RP   AND MUTAGENESIS OF CYS-307 AND TRP-341.
RX   PubMed=16916645; DOI=10.1016/j.molcel.2006.06.024;
RA   Machida Y.J., Machida Y., Chen Y., Gurtan A.M., Kupfer G.M.,
RA   D'Andrea A.D., Dutta A.;
RT   "UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative
RT   autoregulation.";
RL   Mol. Cell 23:589-596(2006).
RN   [9]
RP   FUNCTION, INTERACTION WITH UBE2T, AND MUTAGENESIS OF CYS-307 AND
RP   CYS-310.
RX   PubMed=17938197; DOI=10.1128/MCB.00504-07;
RA   Alpi A., Langevin F., Mosedale G., Machida Y.J., Dutta A., Patel K.J.;
RT   "UBE2T, the Fanconi anemia core complex, and FANCD2 are recruited
RT   independently to chromatin: a basis for the regulation of FANCD2
RT   monoubiquitination.";
RL   Mol. Cell. Biol. 27:8421-8430(2007).
RN   [10]
RP   INTERACTION WITH HES1, AND SUBCELLULAR LOCATION.
RX   PubMed=18550849; DOI=10.1182/blood-2008-04-152710;
RA   Tremblay C.S., Huang F.F., Habi O., Huard C.C., Godin C., Levesque G.,
RA   Carreau M.;
RT   "HES1 is a novel interactor of the Fanconi anemia core complex.";
RL   Blood 112:2062-2070(2008).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH UBE2T AND UBE2W, AND
RP   MUTAGENESIS OF 158-TYR-PRO-159; CYS-307 AND CYS-359.
RX   PubMed=19111657; DOI=10.1016/j.molcel.2008.12.003;
RA   Alpi A.F., Pace P.E., Babu M.M., Patel K.J.;
RT   "Mechanistic insight into site-restricted monoubiquitination of FANCD2
RT   by Ube2t, FANCL, and FANCI.";
RL   Mol. Cell 32:767-777(2008).
RN   [12]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF CYS-307.
RX   PubMed=19589784; DOI=10.1074/jbc.C109.038075;
RA   Longerich S., San Filippo J., Liu D., Sung P.;
RT   "FANCI binds branched DNA and is monoubiquitinated by UBE2T-FANCL.";
RL   J. Biol. Chem. 284:23182-23186(2009).
RN   [13]
RP   IDENTIFICATION IN THE FA COMPLEX.
RX   PubMed=22343915; DOI=10.1182/blood-2011-10-385963;
RA   Ali A.M., Pradhan A., Singh T.R., Du C., Li J., Wahengbam K.,
RA   Grassman E., Auerbach A.D., Pang Q., Meetei A.R.;
RT   "FAAP20: a novel ubiquitin-binding FA nuclear core-complex protein
RT   required for functional integrity of the FA-BRCA DNA repair pathway.";
RL   Blood 119:3285-3294(2012).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 109-294, INTERACTION WITH
RP   FANCI AND UBE2T, AND MUTAGENESIS OF 127-VAL-TYR-128; LEU-149; PHE-166;
RP   212-TRP--LEU-214; LEU-248; PHE-252; LEU-254 AND ILE-265.
RX   PubMed=21775430; DOI=10.1074/jbc.M111.244632;
RA   Hodson C., Cole A.R., Lewis L.P., Miles J.A., Purkiss A., Walden H.;
RT   "Structural analysis of human FANCL, the E3 ligase in the Fanconi
RT   anemia pathway.";
RL   J. Biol. Chem. 286:32628-32637(2011).
CC   -!- FUNCTION: Ubiquitin ligase protein that mediates
CC       monoubiquitination of FANCD2, a key step in the DNA damage
CC       pathway. Also mediates monoubiquitination of FANCI. May stimulate
CC       the ubiquitin release from UBE2W. May be required for proper
CC       primordial germ cell proliferation in the embryonic stage, whereas
CC       it is probably not needed for spermatogonial proliferation after
CC       birth. {ECO:0000269|PubMed:12973351, ECO:0000269|PubMed:16916645,
CC       ECO:0000269|PubMed:17938197, ECO:0000269|PubMed:19111657,
CC       ECO:0000269|PubMed:19589784}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine. {ECO:0000269|PubMed:12973351,
CC       ECO:0000269|PubMed:16916645, ECO:0000269|PubMed:19111657,
CC       ECO:0000269|PubMed:19589784}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with GGN (By similarity). Belongs to the
CC       multisubunit FA complex composed of FANCA, FANCB, FANCC, FANCE,
CC       FANCF, FANCG, FANCL/PHF9 and FANCM. The complex is not found in FA
CC       patients. In complex with FANCF, FANCA and FANCG, but not with
CC       FANCC, nor FANCE, interacts with HES1; this interaction may be
CC       essential for the stability and nuclear localization of FA core
CC       complex proteins. Interacts with FANCI. Interacts (via the RING-
CC       type zinc finger) with UBE2T and UBE2W. {ECO:0000250,
CC       ECO:0000269|PubMed:12973351, ECO:0000269|PubMed:15502827,
CC       ECO:0000269|PubMed:16116422, ECO:0000269|PubMed:16916645,
CC       ECO:0000269|PubMed:17938197, ECO:0000269|PubMed:18550849,
CC       ECO:0000269|PubMed:19111657, ECO:0000269|PubMed:21775430,
CC       ECO:0000269|PubMed:22343915}.
CC   -!- INTERACTION:
CC       Q8IYA8:CCDC36; NbExp=3; IntAct=EBI-2339898, EBI-8638439;
CC       Q9NX63:CHCHD3; NbExp=3; IntAct=EBI-2339898, EBI-743375;
CC       Q8NF50-2:DOCK8; NbExp=3; IntAct=EBI-2339898, EBI-10174653;
CC       Q9NRA8:EIF4ENIF1; NbExp=3; IntAct=EBI-2339898, EBI-301024;
CC       P28799:GRN; NbExp=3; IntAct=EBI-2339898, EBI-747754;
CC       Q9UKT9:IKZF3; NbExp=3; IntAct=EBI-2339898, EBI-747204;
CC       Q9BVG8:KIFC3; NbExp=3; IntAct=EBI-2339898, EBI-2125614;
CC       Q9BRK4:LZTS2; NbExp=3; IntAct=EBI-2339898, EBI-741037;
CC       Q8IUH3:RBM45; NbExp=3; IntAct=EBI-2339898, EBI-2512147;
CC       Q9UFD9:RIMBP3; NbExp=3; IntAct=EBI-2339898, EBI-10182375;
CC       Q9Y2D8:SSX2IP; NbExp=3; IntAct=EBI-2339898, EBI-2212028;
CC       Q12800:TFCP2; NbExp=3; IntAct=EBI-2339898, EBI-717422;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NW38-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NW38-2; Sequence=VSP_041727;
CC   -!- DOMAIN: The UBC-RWD region (URD) region mediates interaction with
CC       FANCI and FANCD2. {ECO:0000269|PubMed:21775430}.
CC   -!- PTM: The RING-type zinc finger domain is monoubiquitinated in the
CC       presence of UBE2T and UBE2W.
CC   -!- DISEASE: Fanconi anemia complementation group L (FANCL)
CC       [MIM:614083]: A disorder affecting all bone marrow elements and
CC       resulting in anemia, leukopenia and thrombopenia. It is associated
CC       with cardiac, renal and limb malformations, dermal pigmentary
CC       changes, and a predisposition to the development of malignancies.
CC       At the cellular level it is associated with hypersensitivity to
CC       DNA-damaging agents, chromosomal instability (increased chromosome
CC       breakage) and defective DNA repair. {ECO:0000269|PubMed:12973351}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- CAUTION: Although PubMed:12724401 reports that it contains a PHD-
CC       type zinc finger, it contains a RING-type zinc finger. Moreover,
CC       PHD-type zinc fingers do not have any ubiquitin ligase activity.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Fanconi Anemia Mutation Database;
CC       URL="http://www.rockefeller.edu/fanconi/mutate/jumpl.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK001197; BAA91548.1; -; mRNA.
DR   EMBL; AC007250; AAY15020.1; -; Genomic_DNA.
DR   EMBL; BC009042; AAH09042.1; -; mRNA.
DR   EMBL; BC054517; AAH54517.1; -; mRNA.
DR   EMBL; BC037570; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS1860.1; -. [Q9NW38-1]
DR   CCDS; CCDS46294.1; -. [Q9NW38-2]
DR   RefSeq; NP_001108108.1; NM_001114636.1. [Q9NW38-2]
DR   RefSeq; NP_060532.2; NM_018062.3. [Q9NW38-1]
DR   UniGene; Hs.631890; -.
DR   PDB; 3ZQS; X-ray; 2.00 A; A/B=109-294.
DR   PDB; 4CCG; X-ray; 2.40 A; X/Y=288-375.
DR   PDBsum; 3ZQS; -.
DR   PDBsum; 4CCG; -.
DR   ProteinModelPortal; Q9NW38; -.
DR   SMR; Q9NW38; -.
DR   BioGrid; 120429; 34.
DR   DIP; DIP-43975N; -.
DR   IntAct; Q9NW38; 40.
DR   MINT; MINT-2819517; -.
DR   STRING; 9606.ENSP00000385021; -.
DR   iPTMnet; Q9NW38; -.
DR   PhosphoSitePlus; Q9NW38; -.
DR   BioMuta; FANCL; -.
DR   DMDM; 116241360; -.
DR   EPD; Q9NW38; -.
DR   MaxQB; Q9NW38; -.
DR   PaxDb; Q9NW38; -.
DR   PeptideAtlas; Q9NW38; -.
DR   PRIDE; Q9NW38; -.
DR   Ensembl; ENST00000233741; ENSP00000233741; ENSG00000115392. [Q9NW38-1]
DR   Ensembl; ENST00000402135; ENSP00000385021; ENSG00000115392. [Q9NW38-2]
DR   GeneID; 55120; -.
DR   KEGG; hsa:55120; -.
DR   UCSC; uc002rzw.5; human. [Q9NW38-1]
DR   CTD; 55120; -.
DR   DisGeNET; 55120; -.
DR   GeneCards; FANCL; -.
DR   GeneReviews; FANCL; -.
DR   HGNC; HGNC:20748; FANCL.
DR   HPA; CAB033842; -.
DR   HPA; HPA036685; -.
DR   HPA; HPA036686; -.
DR   MalaCards; FANCL; -.
DR   MIM; 608111; gene.
DR   MIM; 614083; phenotype.
DR   neXtProt; NX_Q9NW38; -.
DR   OpenTargets; ENSG00000115392; -.
DR   Orphanet; 84; Fanconi anemia.
DR   PharmGKB; PA134887656; -.
DR   eggNOG; KOG3268; Eukaryota.
DR   eggNOG; ENOG410YC2U; LUCA.
DR   GeneTree; ENSGT00390000005537; -.
DR   HOGENOM; HOG000007643; -.
DR   HOVERGEN; HBG045632; -.
DR   InParanoid; Q9NW38; -.
DR   KO; K10606; -.
DR   OMA; PKMLPEC; -.
DR   OrthoDB; EOG091G0PRR; -.
DR   PhylomeDB; Q9NW38; -.
DR   TreeFam; TF323571; -.
DR   Reactome; R-HSA-6783310; Fanconi Anemia Pathway.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; FANCL; human.
DR   GeneWiki; FANCL; -.
DR   GenomeRNAi; 55120; -.
DR   PRO; PR:Q9NW38; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000115392; -.
DR   CleanEx; HS_FANCL; -.
DR   ExpressionAtlas; Q9NW38; baseline and differential.
DR   Genevisible; Q9NW38; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0043240; C:Fanconi anaemia nuclear complex; IDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005635; C:nuclear envelope; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:MGI.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IMP:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; IMP:UniProtKB.
DR   GO; GO:0007276; P:gamete generation; IEA:Ensembl.
DR   GO; GO:0036297; P:interstrand cross-link repair; TAS:Reactome.
DR   GO; GO:0006513; P:protein monoubiquitination; IDA:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; IEA:Ensembl.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR026848; Fancl.
DR   InterPro; IPR026850; FANCL_C.
DR   InterPro; IPR019162; FancL_WD-rpt_cont_dom.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR13206; PTHR13206; 1.
DR   Pfam; PF11793; FANCL_C; 1.
DR   Pfam; PF09765; WD-3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Cytoplasm; DNA damage; DNA repair; Fanconi anemia; Metal-binding;
KW   Nucleus; Polymorphism; Reference proteome; Transferase;
KW   Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22814378}.
FT   CHAIN         2    375       E3 ubiquitin-protein ligase FANCL.
FT                                /FTId=PRO_0000055908.
FT   ZN_FING     307    365       RING-type.
FT   REGION      104    294       UBC-RWD region (URD).
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:22814378}.
FT   VAR_SEQ     178    178       T -> TPQVNS (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_041727.
FT   VARIANT     144    144       S -> F (in dbSNP:rs36059257).
FT                                /FTId=VAR_052082.
FT   MUTAGEN     127    128       VY->AA: Does not affect interaction with
FT                                FANCI and FANCD2.
FT                                {ECO:0000269|PubMed:21775430}.
FT   MUTAGEN     149    149       L->A: Does not affect interaction with
FT                                FANCI and FANCD2; when associated with A-
FT                                166. {ECO:0000269|PubMed:21775430}.
FT   MUTAGEN     158    159       YP->AA: Abolishes UBE2T charging.
FT                                {ECO:0000269|PubMed:19111657}.
FT   MUTAGEN     166    166       F->A: Does not affect interaction with
FT                                FANCI and FANCD2; when associated with A-
FT                                149. {ECO:0000269|PubMed:21775430}.
FT   MUTAGEN     212    214       WVL->AVA: Impairs interaction with FANCI
FT                                and FANCD2.
FT                                {ECO:0000269|PubMed:21775430}.
FT   MUTAGEN     248    248       L->A: Impairs interaction with FANCI and
FT                                FANCD2; when associated with A-252.
FT                                {ECO:0000269|PubMed:21775430}.
FT   MUTAGEN     252    252       F->A: Impairs interaction with FANCI and
FT                                FANCD2; when associated with A-248.
FT                                {ECO:0000269|PubMed:21775430}.
FT   MUTAGEN     254    254       L->A: Impairs interaction with FANCI and
FT                                FANCD2; when associated with A-265.
FT                                {ECO:0000269|PubMed:21775430}.
FT   MUTAGEN     265    265       I->A: Impairs interaction with FANCI and
FT                                FANCD2; when associated with A-254.
FT                                {ECO:0000269|PubMed:21775430}.
FT   MUTAGEN     307    307       C->A: Abolishes ubiquitin ligase
FT                                activity. {ECO:0000269|PubMed:12973351,
FT                                ECO:0000269|PubMed:16916645,
FT                                ECO:0000269|PubMed:17938197,
FT                                ECO:0000269|PubMed:19111657,
FT                                ECO:0000269|PubMed:19589784}.
FT   MUTAGEN     310    310       C->A: Abolishes ubiquitin ligase
FT                                activity. {ECO:0000269|PubMed:12973351,
FT                                ECO:0000269|PubMed:17938197}.
FT   MUTAGEN     341    341       W->G: Abolishes interaction with UBE2T
FT                                and ubiquitin ligase activity.
FT                                {ECO:0000269|PubMed:16916645}.
FT   MUTAGEN     359    359       C->A: Abolishes ubiquitin ligase
FT                                activity. {ECO:0000269|PubMed:19111657}.
FT   CONFLICT     77     77       S -> P (in Ref. 1; BAA91548).
FT                                {ECO:0000305}.
FT   HELIX       114    121       {ECO:0000244|PDB:3ZQS}.
FT   HELIX       123    125       {ECO:0000244|PDB:3ZQS}.
FT   STRAND      126    129       {ECO:0000244|PDB:3ZQS}.
FT   STRAND      133    141       {ECO:0000244|PDB:3ZQS}.
FT   STRAND      147    153       {ECO:0000244|PDB:3ZQS}.
FT   TURN        156    160       {ECO:0000244|PDB:3ZQS}.
FT   STRAND      164    166       {ECO:0000244|PDB:3ZQS}.
FT   HELIX       183    196       {ECO:0000244|PDB:3ZQS}.
FT   HELIX       198    210       {ECO:0000244|PDB:3ZQS}.
FT   STRAND      213    218       {ECO:0000244|PDB:3ZQS}.
FT   STRAND      225    231       {ECO:0000244|PDB:3ZQS}.
FT   STRAND      234    239       {ECO:0000244|PDB:3ZQS}.
FT   STRAND      250    255       {ECO:0000244|PDB:3ZQS}.
FT   HELIX       257    270       {ECO:0000244|PDB:3ZQS}.
FT   HELIX       271    273       {ECO:0000244|PDB:3ZQS}.
FT   HELIX       280    288       {ECO:0000244|PDB:3ZQS}.
FT   TURN        308    310       {ECO:0000244|PDB:4CCG}.
FT   TURN        327    329       {ECO:0000244|PDB:4CCG}.
FT   HELIX       335    342       {ECO:0000244|PDB:4CCG}.
FT   STRAND      349    351       {ECO:0000244|PDB:4CCG}.
FT   STRAND      354    358       {ECO:0000244|PDB:4CCG}.
FT   TURN        360    362       {ECO:0000244|PDB:4CCG}.
FT   STRAND      365    369       {ECO:0000244|PDB:4CCG}.
SQ   SEQUENCE   375 AA;  42905 MW;  E217DF9D64587E5E CRC64;
     MAVTEASLLR QCPLLLPQNR SKTVYEGFIS AQGRDFHLRI VLPEDLQLKN ARLLCSWQLR
     TILSGYHRIV QQRMQHSPDL MSFMMELKML LEVALKNRQE LYALPPPPQF YSSLIEEIGT
     LGWDKLVYAD TCFSTIKLKA EDASGREHLI TLKLKAKYPA ESPDYFVDFP VPFCASWTPQ
     SSLISIYSQF LAAIESLKAF WDVMDEIDEK TWVLEPEKPP RSATARRIAL GNNVSINIEV
     DPRHPTMLPE CFFLGADHVV KPLGIKLSRN IHLWDPENSV LQNLKDVLEI DFPARAILEK
     SDFTMDCGIC YAYQLDGTIP DQVCDNSQCG QPFHQICLYE WLRGLLTSRQ SFNIIFGECP
     YCSKPITLKM SGRKH
//
